In general in medicine there is a move towards personalized treatment. This will be especially important for type 1 diabetes as this is a very heterogenous disease involving both genetic and environmental factors.
We reported earlier on the researchers’ first results with the diabetes vaccine Diamyd® (GAD65-alum). The researchers now report that the efficacy of Diamyd® is associated with the HLA-DR3-DQ2 and DR4-DQ8 haplotypes: patients with the DR3-DQ2 haplotype show a dose-dependent effect of the vaccine on residual C-peptide production (i.e. beta-cell function), especially when these patients are negative for genotypes that include the HLA-DR4-DQ8 haplotype. They explain their results in this Medical Expert Event.
These results contribute to stratifying patients based on on their genotype, facilitating and accelarating the development of immunomodulatory therapies for type 1 diabetes.